Chimeric Polyamide Compounds Target GAA Repeats in Friedreich's Ataxia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Friedreich's ataxia, caused by defective frataxin gene expression due to GAA trinucleotide repeat expansions, lack effective methods to modulate gene expression and reverse disease progression.
Innovation Solution
Development of chimeric heterocyclic polyamide compounds that recruit regulatory molecules to the frataxin gene, using a recruiting moiety linked to a DNA binding moiety that selectively binds to the GAA trinucleotide repeat sequence, to modulate gene expression and counteract the production of defective frataxin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medical treatments are used for Friedreich's ataxia, then patients receive surgical intervention and symptomatic therapy, but there is no cure and disease progression cannot be reversed
Solution Approach 1:
The patent employs chimeric heterocyclic polyamide compounds as intermediary molecules that bridge the gap between existing knowledge and the desired therapeutic effect. These compounds consist of a DNA-binding domain that specifically recognizes GAA repeat sequences and a recruiting domain that binds regulatory molecules, thereby mediating the recruitment of epigenetic modifiers to the frataxin gene locus to reverse the pathogenic effects of the expansion
Solution Approach 2:
The invention utilizes composite molecular structures combining heterocyclic polyamide scaffolds with specific functional domains. The chimeric compounds integrate a DNA-binding moiety (recognizing GAA repeats) with a recruiting moiety (binding regulatory molecules such as bromodomain proteins), creating a composite therapeutic agent that simultaneously achieves sequence-specific targeting and epigenetic modulation
2Reliability
If GAA trinucleotide repeat expansions are present in the frataxin gene, then frataxin expression is reduced causing disease pathology, but no effective method exists to modulate this expression
Solution Approach 1:
The patent extracts and targets the specific pathogenic element (GAA repeat expansion) within the frataxin gene intron. By designing compounds that specifically bind to GAA repeat sequences, the invention isolates the problem site and applies targeted epigenetic modulation only at this location, leaving the rest of the gene and genome unaffected
Solution Approach 2:
The invention changes the epigenetic parameters (histone modifications, chromatin accessibility) at the frataxin gene locus through recruitment of regulatory molecules. By altering these biochemical parameters, the compound transforms the transcriptional state of the gene from repressed to active, thereby restoring frataxin expression without modifying the underlying GAA repeat sequence
3Reliability
If regulatory molecules are recruited to the frataxin gene, then defective frataxin expression can be counteracted, but this requires novel compound design
Solution Approach 1:
The chimeric polyamide compounds are segmented into distinct functional modules: a DNA-binding domain containing heterocyclic units that recognize specific base pairs in the GAA repeat, a linker region providing structural flexibility, and a recruiting domain that binds regulatory molecules. This segmentation allows each component to be optimized independently while maintaining overall functionality
Solution Approach 2:
The heterocyclic polyamide scaffold serves as an intermediary structure that translates the sequence-specific DNA binding event into recruitment of regulatory molecules. The compound acts as a molecular bridge, converting the static DNA sequence information into dynamic epigenetic regulation through its dual-binding capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the occurrence, severity, and frequency of symptoms associated with Friedreich's ataxia by selectively binding to the GAA repeat sequence and recruiting regulatory molecules to downregulate defective frataxin gene expression.
Implementation Method 1
these inhibitors generally act via noncovalent binding to the regulatory molecules
Implementation Method 2
Small molecule inhibitors of regulatory molecules serve as templates for the design of recruiting moieties, since these inhibitors generally act via noncovalent binding to the regulatory molecules
Data Source
AI summary
The present disclosure relates to compounds and methods which may be useful for modulating the expression of fxn and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.